Real‐world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer's disease: a multicenter longitudinal cohort study in Jiangsu, China
Year: 2026
Type: article
Abstract: INTRODUCTION: Real-world data on lecanemab's efficacy and the longitudinal dynamics of plasma biomarkers are scarce in Chinese patients with Alzheimer's disease (AD). METHODS: In this multicenter cohort study, 181 AD patients received biweekly lecanemab. Disease-stage-specific Clinical Dementia Rating-Sum of Boxes meaningful within-patient change defined response at Months 3, 6, and 12. We used penalized models, receiver operating characteristic analysis, attrition comparisons, and exploratory Month 3 plasma biomarker analysis. RESULTS: Cognitive response emerged at Month 6 and intensified by Month 12, largely restricted to mild cognitive impairment and mild dementia due to AD. Repeated five-fold cross-validated areas under the curve across the follow-up timepoints were 0.560, 0.747, and 0.773, with apolipoprotein E ε4 positivity and more severe cognitive impairment linked to lower response odds. Plasma phosphorylated tau 217 (p-tau217) and amyloid beta (Aβ) 42/40 altered as early as Month 3. Month 3 Aβ42/40 showed modest exploratory discrimination. The incidence of amyloid-related imaging abnormalities was 7.2%, all asymptomatic. DISCUSSION: Lecanemab is effective and safe in AD over 6 to 12 months. Early biomarker changes (p-tau217, Aβ42/40) precede clinical improvement, serving as scalable response indicators.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.71936
Authors: Limoran Tang, Xicheng Chen, Li Zhang, Lin Fan, Nihong Chen, Chaosheng Li, Zenglin Cai, Guofang Chen, Haifeng Chen, Min Ye, Huifen Zheng, Qi Li, Zhihong Ke, Zheqi Hu, Maohong Cao, Dan Yang, Shuai Xu, Chunming Xie, Xiaobo Li, Xiaotian Xu, Ming Yu, Xuegan Lian, Hua Hu, Hongfei Li, Xiuying Cai, Hong Chen, Wu Xu, Guiyun Cui, Yang Zhao, Jingde Dong, Lili Zhang, Xiaolei Zhu, Hui Zhao, Yun Xu
Institutions: Nanjing Drum Tower Hospital, Jiangsu Cancer Hospital, Nanjing University, Nanjing Medical University, Nanjing Brain Hospital, Wuxi Fourth People's Hospital, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Nanjing First Hospital, Xuzhou Central Hospital, Affiliated Hospital of Nantong University, Zhongda Hospital Southeast University, Southeast University, Yangzhou University, Northern Jiangsu People's Hospital, Affiliated Hospital of Jiangsu University, Soochow University, Second Affiliated Hospital of Soochow University, First Affiliated Hospital of Soochow University, Taixing People's Hospital, State Key Laboratory of Pharmaceutical Biotechnology
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
OpenAlex ID: W7223991842